Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating if circulating tumor HPV DNA ctHPVDNA in blood plasma and transrenal HPV DNA TrHPVDNA in urine can serve as non-invasive markers to detect and monitor cervical cancer. This study aims to understand the relationship between these DNA levels and the presence of cervical cancer at diagnosis and after treatment. The goal is to improve early detection of recurrence and guide personalized treatment decisions using these biomarkers. Participants diagnosed with cervical cancer will provide blood and urine samples before treatment and again 2 to 6 weeks after completing surgery or chemoradiation. Archived or leftover tissue samples may also be accessed. The study does not involve experimental treatments but focuses on collecting and analyzing biological samples to monitor disease status. During the study, participants will have their plasma and urine tested for ctHPVDNA and TrHPVDNA levels at baseline and post-treatment. Researchers will compare these results to evaluate changes correlated with treatment response. The main outcome is the relationship between these biomarkers and cervical cancer presence. The study will also track changes in these DNA levels following definitive therapy, with participation lasting through the post-treatment sample collection period.
Actively Recruiting
Researchers are evaluating the Enhanced Friendship Bench intervention to improve perinatal depression, HIV care engagement, and infant health outcomes among pregnant women with HIV and depression in Malawi. This fully powered randomized controlled trial aims to confirm the interventions effectiveness, study how it works, and gather important data to help apply the findings in real-world settings. The study follows up on a pilot trial that showed promising results for improving mental health and HIV care during and after pregnancy. Participants will receive either the Enhanced Friendship Bench intervention or enhanced usual care. The Enhanced Friendship Bench includes problem-solving therapy with four prenatal and two postnatal counseling sessions, two social support sessions, and monthly home visits for ART delivery and counseling during the third trimester and first three months postpartum. The comparison group will receive usual outpatient care enhanced with mental health evaluations, brief counseling, education about mental health, and referral support when needed. Throughout the study, participants will be monitored for changes in depressive symptoms and HIV care retention six months after giving birth. Infant growth measurements will also be taken at six months postpartum, including height-for-age, weight-for-age, and weight-for-height. Additional assessments include depression remission and HIV viral suppression up to twelve months postpartum. The study uses double-masked methods and randomizes participants to either group, with ongoing evaluations to track health outcomes and treatment engagement over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the PAC-Man model, an integrated differentiated service delivery approach designed to eliminate mother-to-child transmission of HIV in Malawi. This study compares the PAC-Man model to the standard care currently provided by the Ministry of Health. The trial aims to measure the effect of the PAC-Man model on timely early infant diagnosis testing and guideline-adherent viral load testing among pregnant and breastfeeding women living with HIV. It also assesses implementation outcomes of these strategies using a hybrid effectiveness-implementation stepped-wedge design across 12 health facility sites grouped into four clusters. The PAC-Man model includes three key evidence-based practices delivered via mobile care teams in community settings pediatric active case finding using novel point-of-care early infant diagnosis technology, same-day antiretroviral therapy initiation for infants newly diagnosed with HIV, and maternal viral load testing with back-to-care services. These mobile teams deploy diagnostic technology called m-PIMA and use task shifting, where community health workers and nurses provide services at convenient community locations to improve access and adherence. The intervention is compared against routine care provided by the Ministry of Health. Participants include mother-infant pairs enrolled in the national EMTCT program, high-risk pregnant or breastfeeding women with HIV, healthcare providers, and policy makers. Data collection involves surveys, interviews, focus groups, and implementation actor questionnaires. The study measures include the proportion of infants receiving early infant diagnosis by six months, viral load testing for mothers, ART initiation rates, and retention in care. Outcomes are tracked within 12 months of enrollment, and implementation costs and adoption rates are also evaluated. The trial is conducted under routine care conditions and runs until March 2028.
Actively Recruiting
Researchers are analyzing existing medical record data to evaluate different ways of delivering HIV treatment in Malawi. This observational study focuses on understanding the coverage, uptake, benefits, and costs of differentiated service delivery models DSD aimed at improving HIV care. The project seeks to provide information to support future decision-making and ongoing evaluation of these treatment approaches in high-prevalence settings. The study collects routine medical record data from electronic medical record systems, other electronic databases, and paper charts. It compares patients enrolled in DSD models with those not enrolled, examining how different service models are implemented and their impact on patient outcomes. There are no direct interactions with patients, providers, or caregivers during data collection. Participants are people living with HIV aged 15 years and older who received care during the data collection period. Researchers will analyze outcomes such as the number of patient-months enrolled in any DSD model over 6, 12, and 24 months. The study will assess factors like uptake of DSD, patient health outcomes, and the distribution of service delivery models, helping to inform sustainable HIV treatment strategies without ongoing external donor support.
Actively Recruiting
This research aims to evaluate the implementation of pediatric acute myeloid leukemia AML treatment guidelines adapted for resource-limited settings like Malawi. The study focuses on children under 18 years diagnosed with de novo AML at Kamuzu Central Hospital, where survival rates are notably low. It assesses a clinical practice guideline CPG based on recommendations by the International Society of Paediatric Oncology SIOP, designed to balance effective treatment with manageable side effects in this setting. The study observes patients treated according to the 2023 KCH AML therapy CPG, which is the current standard of care at the hospital. The guideline involves intensity-adapted chemotherapy cycles including induction and consolidation phases, with inpatient care during chemotherapy cycles until recovery milestones. Patients then have a brief home period before the next cycle. Data collection includes routine clinical care measurements like bone marrow evaluations, blood tests, imaging, and patient questionnaires, with no extra procedures required for study participation. Participants will be followed during therapy and after treatment completion, with monthly telephone check-ins for six months and in-person visits up to two years and beyond. The study measures implementation success by combining feasibility and effectiveness, including treatment completion rates and remission outcomes. Additional outcomes include survival, adverse events, hematologic recovery, cytogenetics, and quality of life assessments. This is the first prospective pediatric AML study in sub-Saharan Africa aimed at improving care in low-resource environments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effectiveness and implementation of the LINK model, a clinical intervention designed to improve Pre-exposure Prophylaxis PrEP persistence among postpartum women in Lilongwe, Malawi. The study compares the LINK model to the standard of care across twelve randomized sites to determine if the LINK model improves PrEP use during the postpartum period in a high HIV incidence setting. The LINK model includes linking postpartum HIV testing and PrEP services to early infant vaccination visits, screening for HIV risk at these visits, engaging male partners to support PrEP use, and community-facility linkage with peer mothers providing support for breastfeeding women using PrEP. These components are integrated into existing clinic workflows and delivered by healthcare assistants and peer mothers alongside routine Ministry of Health PrEP services. Women at control sites receive the usual standard of care. Participants include postpartum women receiving infant vaccinations and PrEP care. Data collection involves reviewing medical records, health surveillance data, surveys, in-depth interviews, and dried blood spot testing to assess PrEP adherence. The primary outcomes measure PrEP persistence and uptake, with monitoring through existing records and study tools over approximately 3.5 years. The study also gathers feedback on the acceptability and feasibility of the intervention from women and stakeholders.
Actively Recruiting
This research focuses on people living with HIV in sub-Saharan Africa who have unexplained lymphadenopathy, a swollen lymph node condition that may indicate serious diseases like tuberculosis, lymphoma, or multicentric Castleman disease MCD. The study aims to develop and evaluate new diagnostic methods to better identify lymphoma and MCD, addressing delays and missed diagnoses that currently occur in this population. It specifically investigates the use of a novel nucleic acid measurement assay to detect viruses linked to these diseases. The study uses an innovative device called the Tiny Isothermal Nucleic acid Amplification System TINY to analyze samples from fine needle aspirations and biopsies. This device measures nucleic acids related to Epstein-Barr virus EBV and Kaposi sarcoma herpesvirus KSHV, which are important markers for lymphoma and MCD. Participants are HIV-infected patients with unexplained lymphadenopathy, and their samples will undergo testing by TINY and other methods like Gene Xpert and quantitative PCR. Participants will be involved in providing samples through fine needle aspiration or lymph nodecore needle biopsy. Researchers will collect clinical and laboratory data at enrollment, evaluating the diagnostic performance of the TINY device for detecting EBV and KSHV DNA. The main outcome is the number of patients diagnosed using these new approaches. The study will continue until December 2028, with ongoing assessments during enrollment to monitor results and safety.
Actively Recruiting
Repeat and prolonged treatment interruption TI among people living with HIV is a major challenge to controlling the HIV epidemic in eastern and southern Africa, including Malawi. This research aims to evaluate an innovative long-term dynamic choice intervention called CHOICE, designed to support ART clients experiencing TI. The trial compares the CHOICE approach with standard care to see if it improves viral suppression after 12 months of follow-up. The CHOICE intervention offers person-centered counseling combined with ongoing, flexible choices about how clients receive their HIV care services. Participants can choose their ART dispensing intervals 1, 3, or 6 months, locations for ART distribution facility, home, or community, and peer mentorship options. These choices can be adjusted at any visit or by phone during the 24-month study period. The control group receives standard care, which includes 1-3 counseling sessions and routine facility-based services without these dynamic choices. Participants will be followed for 12 months to measure viral suppression, with additional monitoring up to 24 months for repeat treatment interruptions, ART coverage, and safety. The study involves regular assessments including viral load tests and will collect data on barriers and facilitators of care as well as the costs and cost-effectiveness of the intervention. This trial aims to find better ways to provide long-term, personalized support to those at risk of treatment interruption.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a package of strategies to help people continue using pre-exposure prophylaxis PrEP for HIV prevention, focusing especially on long-acting injectable cabotegravir CAB LA. This study compares standard care with an enhanced support program across various clinics and community centers serving prioritized groups such as female sex workers, men who have sex with men, transgender individuals, and others at high risk. The goal is to see which approach better supports ongoing use of PrEP over time. Participants in the study will be part of clusters randomized to either receive the standard Ministry of Health care for PrEP continuation or an enhanced bundle of support including improved communication, peer support, and flexible clinic hours. The study uses passive enrollment from clinics and collects data on PrEP initiation, switching between oral and injectable forms, and continuation rates. Additional research includes surveys, interviews, and fidelity assessments to understand the acceptability and implementation of these strategies. Participants will be followed for at least five months after starting PrEP, with data collected through program records and additional research activities. Researchers will measure continuation of CAB LA PrEP use at five months as the main outcome, along with continuation of oral PrEP and other secondary measures. The study includes interviews to capture participant experiences and uses both quantitative and qualitative methods to analyze findings. Follow-up data will span from five to eleven months depending on enrollment timing.
Actively Recruiting
Researchers are studying neurodevelopmental outcomes in children aged 4 to 8 years in Malawi who were born to mothers participating in the Prevention of Prematurity and Xylitol PPaX trial. This study compares children exposed to maternal xylitol chewing gum during pregnancy to those without such exposure, focusing on cognitive, executive function, social-emotional, motor, and language development. The trial includes 1000 children divided equally between formerly preterm and term births, considering the impact of gestational xylitol exposure on these groups. The study does not involve new treatments but evaluates differences based on prior exposure to xylitol chewing gum during pregnancy. Children are stratified into four groups depending on preterm or term birth status and xylitol exposure. Neurodevelopmental assessments include the Malawi Developmental Assessment Tool MDAT, Kaufman Assessment Battery for Children-II KABC-II, EF Touch, Strengths and Difficulties Questionnaire SDQ, Anchor Items in Measuring Early Childhood Development AIM-ECD, and the International Development and Early Learning Assessment IDELA. Mothers may also be invited for anthropometric and oral health assessments. Participants will undergo one to two clinic visits within one month for neurodevelopmental assessments, hearing, vision, and dental evaluations. Researchers will measure cognitive scores, executive function, social-emotional outcomes, and motor skills using standardized tools. The primary outcome is the overall cognitive score based on the mental processing index. The study monitors these outcomes carefully to understand the effects of gestational xylitol exposure on child development up to age 8.
1-10 of 18
1